Special Issue "Design of Enzyme Inhibitors as Potential Drugs"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2019).
Interests: medicinal chemistry; organic synthesis; biotransformations; enzyme inhibitors; organophosphonates; peptide mimetics; natural products in food
Special Issues and Collections in MDPI journals
Enzyme inhibitors are used as tools for studying mechanisms of enzymatic catalysis and as compounds for treating certain physiologic disorders. Thus, they remain prime targets for drug design because altering enzyme activity has immediate and defined effects. Their utility as mechanistic therapeutic agents is dependent on both the potency of the inhibitor and its specificity toward its target enzyme. This, in turn, depends on the number and type of interactions the inhibitor makes with the enzyme and the overall mode of inhibition.
Rational drug design requires a multidisciplinary approach with necessity for experimental and theoretical background. Its rapid development is mainly attributed to the tremendous advancements in the computer science, statistics, molecular biology, biophysics, biochemistry, medicinal chemistry, pharmacokinetics and pharmacodynamics experienced in the last few decades. A feature that characterizes this process for developing potential leads all known theoretical and experimental knowledge of the enzyme under study is used. The rational inhibitor design does not follow a certain single strategy; instead, such a strategy is a consequence of the experience of the researcher or the collaborative research group.
To achieve a more comprehensive understanding of modes and techniques of design of enzyme inhibitors of medicinal importance, the journal Pharmaceuticals now invites valuable contributions that report original observations, or reviews on that matter.
Prof. Dr. Pawel Kafarski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- rational drug design
- covalent and non-covalent inhibitors
- structure-based drug design
- transition-state analogs
- knowledge-based modeling and design
- fragment-based approaches in drug discovery
- structure-based selectivity design
- multitarget-directed drugs
- activity-based protein profiling
- inhibitors of natural origin
- non-conventional inhibitors.
- Design of Enzyme Inhibitors as Potential Drugs 2020 in Pharmaceuticals (8 articles)